| Name | Title | Contact Details |
|---|
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Prognosis Health Information Systems (PROGNOSIS) is the progeny of an eight year old hospital business software vendor and a thirty-five year old medical records service and software provider which have provided products and services to hospitals across America.
New York Med And Diagnstc Center is a Kew Gardens, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wellpath is the premier provider of localized, high-quality, compassionate care to vulnerable patients in challenging clinical environments. Wellpath holds patients at the center of everything we do and promotes rigorous standards of care and innovation. With nearly 15,000 clinicians and professionals in 35 states across the U.S. and Australia, Wellpath provides medical and mental healthcare services for over 240,000 patients daily in state hospitals, forensic treatment, civil commitment centers, community care centers as well as local, state and federal correctional facilities.
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex`s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product, Tru Niagen® — available at www.truniagen.com and through partnerships with global retailers and distributors.